The goal of the Administration Core for the P01is to provide oversight and coordination for the scientific,administrative, fiscal and regulatory aspects of the P01. Specific functions of the core include:(1) Scientific integration of the projects, review of quarterly progress reports of each project, refining goals, prioritizing and realigning resources to assure the most efficient way of advancing the best leads. This will be accomplished by the guidance of the steering committee under the leadershipof the P01Principal Investigators in consultation with the external advisory board (EAB).(2) Scientific planning and coordination including organizing regular meetings with project and core leaders as well as visits by members of the EAB.(3) Fiscal planning and accountability including communication with the NCI staff about fiscal and administrative matters, and the proper day-to-day expenditures within each project and core;(4) Preparation of non-competing continuation progress reports and documentation of all activities related to the P01, including documenting usage of all cores and productivity measures such asjoint publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA118210-01A1
Application #
7214570
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O4))
Project Start
2006-12-01
Project End
2011-11-30
Budget Start
2007-02-05
Budget End
2008-01-31
Support Year
1
Fiscal Year
2007
Total Cost
$90,559
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Kazi, Aslamuzzaman; Ozcan, Sevil; Tecleab, Awet et al. (2014) Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem 289:11906-15
Ozcan, Sevil; Kazi, Aslamuzzaman; Marsilio, Frank et al. (2013) Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors. J Med Chem 56:3783-805
Treviño, José G; Verma, Monika; Singh, Sandeep et al. (2013) Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Mol Cancer Ther 12:2722-34
Ge, Yiyu; Kazi, Aslamuzzaman; Marsilio, Frank et al. (2012) Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. J Med Chem 55:1978-98
Davis, Rebecca; Pillai, Smitha; Lawrence, Nicholas et al. (2012) TNF-?-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle 11:109-18
Kim, Young B; Balasis, Maria E; Doi, Kenichiro et al. (2012) Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction. Bioorg Med Chem Lett 22:5961-5
Johnson, Jackie L; Pillai, Smitha; Pernazza, Danielle et al. (2012) Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res 72:516-26
Doi, Kenichiro; Li, Rongshi; Sung, Shen-Shu et al. (2012) Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 287:10224-35
Li, X; Gilkes, D; Li, B et al. (2012) Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 31:3721-32
Win-Piazza, Hla; Schneeberger, Valentina E; Chen, Liwei et al. (2012) Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2. Cancer Lett 320:81-5

Showing the most recent 10 out of 39 publications